查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861433

登革热检测市场按检测类型、技术、最终用户、产品类型、安装环境和检体类型划分－全球预测（2025-2032 年）

Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，登革热检测市场规模将达到 8.3512 亿美元，复合年增长率为 5.92%。

关键市场统计数据
基准年 2024 5.2702亿美元
预计年份：2025年 5.5861亿美元
预测年份 2032 8.3512亿美元
复合年增长率 (%) 5.92%

我们将介绍目前的登革热诊断环境，包括不断发展的检测方法、实施挑战以及在医疗环境中进行临床判断的必要性。

由于科技的快速发展、医疗服务模式的变革以及公共卫生重点的调整，登革热诊断正处于关键时刻。儘管准确快速的检测仍然是有效临床管理和疫情控制的基础，但从血清学、抗原检测到分子检测等多种检测方法的多样性，给临床医生、实验室技术人员和采购经理带来了复杂的决策环境，需要在临床需求、运营限制和监管要求之间进行周密的协调。

传统上，基于实验室的分子诊断平台提供最高的分析灵敏度，而照护现场抗原检测则侧重于速度和便利性。然而，随着侧向流动化学、微阵列平台和即时聚合酵素链锁反应仪器等技术的进步，这些差异正在变得模糊，性能、单次检测成本和部署灵活性方面的差距正在缩小。同时，全球分散式检查和强化监测的趋势，推动了对检验于多种检体（包括血浆、血清和全血）的检测方法的需求，以及对能够与电子健康系统整合以实现病例报告和流行病学监测的解决方案的需求。

在此背景下，相关人员需要权衡临床绩效指标（例如灵敏度、特异性和检测窗口）与实际操作因素（例如检测量、低温运输要求以及诊所和照护现场的培训需求）。随着登革热在流行地区和新确诊地区持续出现，选择和部署适合当地实验室基础设施和患者诊疗流程的诊断方法，将是降低发病率和优化资源利用的关键因素。

快速的平台创新、检测的去中心化以及不断变化的监管法规正在重塑诊断路径，并加速其在整个医疗保健系统中的应用。

过去五年，登革热检测的研发、检验和应用方式发生了突破性变革。检测化学和平台工程的进步提升了多种检测方法的分析性能，使得抗原检测能够更快地获得结果，分子检测能够提高通量并实现自动化。同时，数位转型也在推动诊断设备与实验室资讯系统的连接，从而实现即时报告并整合到监控网路中。最终，一个响应更迅速的诊断生态系统得以构建，能够更有效地支持疫情爆发检测和临床分诊。

同时，检测分散化趋势显着。简化的工作流程和较低的训练要求促使快速抗原和抗体检测在照护现场和门诊诊所得到更广泛的应用。携带式PCR仪和读数仪的投资也推动了这一转变，使分子检测能够在患者附近进行。因此，医疗系统正在重新评估其诊断流程，以平衡快速筛检检测和分子确诊检测，从而在确保诊断准确性的同时优化资源配置。

市场动态也受到新的监管路径和对实际应用效能数据日益重视的影响。卫生部门正着重进行上市后监测和有条件核准，优先考虑在不影响可靠性的前提下实现快速获取。同时，诊断试剂生产商、学术团体和公共卫生机构之间的策略联盟正在加速检验研究，并推动创新检测方法的快速部署。这些变化共同推动了登革热检测方法的转变，使其更加灵活、协作和临床整合，并优先考虑速度、准确性和操作适用性。

评估2025年美国关税对供应链调整、采购应对措施以及诊断性采购和营运的策略影响

美国将于2025年实施的新关税，为采购登革热诊断组件和成品检测套组的机构带来了更多挑战。这些针对进口设备、试剂和部分检测套组组件的关税，增加了从受影响地区采购某些物品的直接成本，迫使采购团队重新评估筹资策略和总到岸成本。供应商和医疗系统正在透过重新评估其供应商组合、探索区域性生产替代方案以及重组分销协议来应对这一挑战，以减轻眼前的成本负担。

除了采购成本压力外，关税环境也影响供应链设计和库存管理。国内供应选择有限的企业正在提高安全库存水准并延长计画週期，以应对进口成本波动和潜在的前置作业时间延长。同时，供应商正在加快关键设备（例如读数仪和聚合酵素连锁反应热迴圈仪）以及重要耗材和试剂的本地化生产，但这些努力需要资金投入和时间才能实施。在此期间，一些买家正在谈判长期合约以确保以可预测的价格获得供应，而另一些买家则正在分散供应商来源以降低风险。

关税引发的重组也影响竞争格局。拥有垂直整合供应链和本地生产基地的製造商透过提供更稳定的价格和更短的前置作业时间，获得了比较优势。同时，依赖跨境采购的小型供应商则面临证明其定价合理性和确保供应连续性的压力。受预算限制的公共卫生项目和医院尤其容易受到这些变化的影响，它们正在重新评估其采购优先事项。这包括转向那些具有成本效益的临床效用并最大限度减少对受关税影响的投入品依赖的检测方法和平台。

基于深度细分的诊断洞察，解释了测试类型、技术、最终用户、产品形式、安装环境和检体基质如何决定实施选择。

了解市场区隔动态对于选择合适的诊断策略以及使产品系列与使用者需求相符至关重要。从检测类型、抗体、抗原和分子检测选项的角度分析市场格局，可以清楚地展现临床和操作方面的权衡取舍。抗体检测（分为IgG和IgM检测）在先前接触评估和血清流行病学调查中发挥重要作用，而抗原检测（包括NS1酵素免疫分析法和快速NS1检测）的优势在于其快速性，有助于早期发现。分子检测，包括常规PCR和即时PCR，仍然是确诊的标准方法，需要高分析灵敏度和基因型资讯。

技术细分也会影响检测方法的应用。酵素免疫分析法）仍然是高通量检测的基础，而采用胶体金或萤光检测技术的侧向流动免疫检测则能够实现真正的即时检测，并提供一系列定量分析功能。微阵列平台增加了多重侦测功能，可用于鑑别诊断和监测。聚合酵素链锁反应）技术，从传统方法到即时方法，为灵敏、特异性的病毒检测提供了基础，从而为临床决策和监测提供资讯。

最终用户的考量也影响产品的选择和实施策略。诊所和照护现场环境倾向于快速、易用且对设备依赖性低的检测方式。诊断实验室优先考虑检测的可重复性和通量。医院则需要在快速分诊和确诊检测之间寻求平衡。研究实验室需要能够支援方法灵活性和深度分析的平台。按产品类型划分，可以突显互补的商业性模式。仪器和读数器，包括聚合酵素连锁反应热迴圈仪和数位读数器，支援平台相关的检测。软体解决方案则实现连接、数据分析和结果管理。检测套组提供常规检测操作所需的耗材。最后，安装环境和检体类型的选择会影响物流和检验策略。中心实验室提供可控环境以支援复杂的工作流程，而照护现场环境则需要检测方法在血浆、血清和全血等不同基质上的稳健性。综合考虑这些细分维度，可以发现哪些领域的设备、生物化学和营运支援方面的投资能够带来最大的临床和商业性回报。

区域诊断重点和实施实务决定了采购和部署策略。

区域趋势将影响诊断方法的优先排序、检验和采购方式。美洲、欧洲、中东和非洲以及亚太地区的实际情况各不相同。在美洲，成熟的检测网络和积极的私营部门参与有利于采用混合模式，将集中式分子检测与分散式检查检测相结合，并辅以门诊和急诊环境下的照护现场抗原检测。某些国家的法规结构为紧急使用和上市后监测提供了明确的途径，使製造商能够在展示实际应用性能的同时扩大分销范围。

欧洲、中东和非洲地区各国监管体系和医疗基础设施的差异导致了检测方法应用模式的多样性。欧洲资源丰富的市场优先考虑统一的检验标准以及与电子健康记录的整合，而中东和北非地区的市场则常常面临物流方面的限制，因此对能够承受低温运输环境波动的、坚固耐用且维护成本低的检测套组和照护现场平台有着很高的需求。联合采购机制和捐助者支持的倡议在扩大资源匮乏地区检测服务的可近性方面发挥关键作用。

亚太地区对大都会圈的高通量检测解决方案和地方性流行区分散诊所的快速诊断方案的需求都非常强劲。该地区多个国家已发展出本地生产能力，这影响着价格和供应稳定性。跨境合作和区域监测网路正在不断加强，促进了数据共用和协调一致的应对策略。综上所述，这些区域特征凸显了诊断选择和部署策略需要根据当地的基础设施、监管路径和流行病学情况进行调整，以实现有效的病例发现和公共卫生影响。

诊断公司如何调整产品系列、生产弹性和数位化能力，以提供一体化的登革热检测解决方案并确保其供应链安全

登革热诊断生态系统中的主要企业和创新者正透过投资产品研发、建立策略伙伴关係关係以及提升生产能力，来因应不断涌现的新需求。这些公司拥有涵盖抗原、抗体和分子诊断的多元化产品系列，能够满足多层次的临床路径需求，提供即时快速筛检和中心实验室确诊检测。检测开发人员和设备製造商之间的策略联盟正在加速整合解决方案的交付，从而减轻终端用户的检验负担，并加快临床应用进程。

商业策略日益强调互联互通和软体服务，以提升诊断平台的效用。一些公司提供的解决方案将读数器和聚合酵素连锁反应热迴圈仪与安全的数据管理系统结合，从而能够更有效率地收集和分析测试数据，有助于改善病例追踪和资源分配。此外，投资本地生产或建立分散式製造伙伴关係的製造商也获得了实际的好处，例如在供应连续性和应对力关税和物流中断方面的能力。

我们也看到市场推广策略的创新。透过培训、在地化检验协助和全面的服务协议为最终用户提供支援的机构，降低了准入门槛，促进了产品的长期应用。规模较小的专业开发公司透过提供可授权或与主要平台供应商联合品牌的利基或高效能检测产品，为生态系统做出了贡献。总而言之，这些倡议凸显了解决方案正朝着整合检测化学、硬体和数位基础设施的方向发展，以满足不同医疗保健环境的实际需求。

为诊断产业领导者提供切实可行的策略步骤，以加强供应链、加速照护现场创新并整合数位化连接，从而推动技术应用。

产业领导者应迅速调整产品开发、供应链策略和客户参与，以适应登革热诊断领域不断变化的实际情况。首先，应优先考虑采购多元化，并探索区域製造伙伴关係，以降低关税造成的成本波动风险，并缩短关键试剂和仪器组件的前置作业时间。投资于灵活的生产合约和双通路采购策略将确保供应的连续性，并增强供应商的议价能力。其次，为了满足快速分流和分散式监测的需求，他们应加快开发和推出与读卡机相容的照护现场抗原检测和侧向层析检测，同时保留用于确诊和基因分型的实验室级分子检测方案。

领导者还需将数位化措施融入其产品蓝图。在设备和阅读器中建立连接性和标准化的数据导出功能，将有助于即时病例报告，提升公共卫生情报水平，并创造附加价值服务机会。同时，他们将专注于终端用户支持，设计简化的工作流程，提供全面的验证方案，并投资培训项目，以降低用户采用的门槛。从商业性角度来看，他们将提供灵活的合约模式，充分考虑公共卫生专案和医院的采购週期，包括按绩效付费合约以及包含设备、耗材和软体服务的捆绑式解决方案。

最后，积极与监管机构和公共卫生相关人员合作，设计反映真实世界应用的检验研究，包括对血浆、血清和全血的评估，以及在中心实验室和照护现场环境中的评估。透明的上市后监测和可靠的真实世界证据将有助于建立信任并促进更广泛的应用。这些综合努力将使企业能够在竞争日益激烈和分散的环境中实现临床相关性、维持供应安全并推动永续成长。

采用严谨的混合方法研究途径，结合专家访谈、实验室检验审查、法规分析和供应链图谱，以产生以营运为导向的洞见。

本研究采用结构化的混合方法，综合运用质性专家访谈、实验室检验审查、监管指南分析以及对同行评审文献和技术白皮书的系统性回顾等方法，对证据进行综合分析。研究重点包括与临床实验室技术人员、感染疾病专家、采购人员和诊断试剂开发人员进行对话，以收集他们对检测性能、操作限制和实施注意事项的现场观点。实验室检验审查检验了代表抗体、抗原和分子检测类别的检测方法的报告分析灵敏度、特异性和操作特性，并重点关注检体基质的适用性和仪器要求。

我们分析了监管指南和政策文件，以了解影响部署时间的因素，例如核准流程、紧急使用法规和上市后监测要求。该调查方法还包括供应链图谱分析，以确定设备、耗材和试剂的采购依赖关係，并评估关税和物流中断带来的风险。在条件允许的情况下，我们对多个资料来源进行了三角验证，以提高结论的可靠性，并突出显示证据有限或不一致的领域。

此调查方法固有的限制包括不同测试类型效能资料的品质和可用性存在差异，以及监管决策和供应链状况的快速变化。为弥补这些局限性，本研究优先收集关键相关人员的意见，并将测试结果与多个独立资讯来源进行检验。最终的分析旨在提供具有实际操作价值的综合信息，而非最终的技术检验，并协助决策者制定兼顾临床和物流因素的实施计划和筹资策略。

对诊断创新、营运完整性和供应链韧性进行全面综合分析，以确定有效的登革热检测策略和专案优先事项。

技术创新、去中心化和供应链重组的整合，为登革热诊断带来了机会和营运挑战。快速抗原检测和改进的侧向层析检测提高了即时病例检测能力，而PCR设备和实验室自动化技术的进步则维持了密集型确诊检测和基因型监测的必要性。同时，贸易政策变化等外部因素使得供应链韧性和筹资策略成为决定采购风险和专案连续性的关键因素。

对于从业人员和决策者而言，需求显而易见：诊断选择必须与临床路径和实际操作相符。这需要对检测类型和技术的优缺点进行严格评估，制定谨慎的筹资策略以减轻外部成本压力，并投资于数位化和培训基础设施以减少实施阻力。采用整合式方法，结合可靠的就地检验、必要时的实验室确认以及数据协作的机构，将更有利于维持诊断的连续性，并支持有效的临床和公共卫生应对措施。

展望未来，诊断技术开发商、医疗系统和监管机构之间持续合作对于将创新成果转化为可及可靠的检测方案至关重要。优先考虑供应链多元化、真实世界检验和以用户为中心的产品设计的相关人员将加速检测技术的普及应用，并改善登革热患者和社区的治疗效果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在现场环境中实施与智慧型手机相容的登革热血清分型快速分子检测
  • 开发一种可同时检测登革热病毒、兹卡和基孔肯雅病毒的多重照护现场诊断方法
  • 整合基于 CRISPR-Cas 的萤光检测方法快速检测登革病毒 RNA（在护理点实施）
  • 利用奈米颗粒增强检测技术的高灵敏度免疫检测法在资源匮乏地区登革热早期诊断的应用
  • 监管核准趋势加速家用登革热抗原检测套组的商业化，并实现数位化报告
  • 利用人工智慧驱动的演算法，分析患者症状和检测结果，即时预测登革热热点地区
  • 透过生物技术公司与公共卫生机构的合作模式，利用行动侦测单元扩大登革热流行地区的监测范围

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 登革热检测市场（依检测类型划分）

  • 抗体检测
    • IgG抗体检测
    • IgM抗体检测
  • 抗原检测
    • Ns1酵素免疫分析法
    • Ns1快速检测
  • 分子检测
    • 常规聚合酵素链锁反应
    • 即时聚合酵素链锁反应

9. 按技术分類的登革热检测市场

  • 酵素免疫分析法
  • 侧向流动免疫检测
    • 胶体金法
    • 萤光免疫分析
  • 微阵列技术
  • 聚合酵素链锁反应
    • 常规聚合酵素链锁反应
    • 即时聚合酵素链锁反应

第十章 依最终用户分類的登革热检测市场

  • 诊所
  • 诊断实验室
  • 医院
  • 研究所

第十一章 登革热检测市场（依产品类型划分）

  • 装置
    • 领导者
    • 聚合酵素连锁反应热迴圈仪
  • 软体解决方案
  • 检测套组

第十二章：登革热检测市场（按地区划分）

  • 中心实验室
  • 护理点

13. 依检体类型分類的登革热检测市场

  • 电浆
  • 血清
  • 全血

14. 各地区的登革热检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 登革热检测市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国登革热检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • bioM 9rieux SA
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Meridian Bioscience, Inc.
    • Chembio Diagnostics, Inc.
Product Code: MRR-69324464D0E5

The Dengue Testing Market is projected to grow by USD 835.12 million at a CAGR of 5.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 527.02 million
Estimated Year [2025] USD 558.61 million
Forecast Year [2032] USD 835.12 million
CAGR (%) 5.92%

Introducing the current dengue diagnostics environment with evolving assay modalities, deployment challenges, and clinical decision imperatives across care settings

Dengue diagnostic capabilities are at a pivotal juncture, shaped by rapid technological progress, shifting care delivery models, and evolving public health priorities. Accurate and timely detection remains foundational to effective clinical management and outbreak control, while the diversity of available assays-from serology to antigen detection to molecular methods-creates a complex decision environment for clinicians, laboratorians, and procurement leaders. The landscape demands careful calibration between clinical needs, operational constraints, and regulatory expectations.

Historically, laboratory-based molecular platforms provided the highest analytical sensitivity, contrasted with point-of-care antigen assays that emphasized speed and simplicity. However, these distinctions are blurring as innovations in lateral flow chemistry, microarray platforms, and real-time polymerase chain reaction instruments narrow gaps in performance, cost per test, and deployment flexibility. In parallel, the global push toward decentralized testing and stronger surveillance has increased demand for assays validated on a range of sample types including plasma, serum, and whole blood, and for solutions that integrate with electronic health systems to enable case reporting and epidemiological monitoring.

Against this backdrop, stakeholders must balance clinical performance metrics such as sensitivity, specificity, and window-of-detection with pragmatic considerations including throughput, cold-chain requirements, and training needs at clinics and point-of-care settings. As dengue continues to circulate in endemic and newly exposed regions, the capacity to choose and implement diagnostics that align with local laboratory infrastructure and patient pathways will be a defining factor in limiting morbidity and optimizing resource use.

How rapid platform innovation, decentralization of testing, and regulatory evolution are reshaping diagnostic pathways and accelerating adoption across healthcare systems

The past five years have seen transformative shifts that are redefining how dengue testing is developed, validated, and delivered. Advances in assay chemistry and platform engineering have lifted analytical performance across multiple categories, enabling antigen tests with faster time-to-result and molecular tests with greater throughput and automation. These technology improvements are being accompanied by digital transformations that connect diagnostic devices to laboratory information systems, enabling real-time reporting and integration into surveillance networks. The result is a more responsive diagnostic ecosystem that can better support outbreak detection and clinical triage.

Simultaneously, there has been a marked movement toward decentralization of testing. Point-of-care settings and outpatient clinics are increasingly equipped to perform rapid antigen and antibody assays, facilitated by simpler workflows and lower training requirements. This shift is complemented by investments in portable PCR instruments and reader devices that allow molecular-level confirmation closer to the patient. As a consequence, healthcare systems are re-evaluating diagnostic algorithms to balance the use of rapid screening assays with confirmatory molecular testing, optimizing resource allocation while preserving diagnostic confidence.

Market dynamics have also been influenced by new regulatory pathways and emphasis on real-world performance data. Health authorities are leaning on post-market surveillance and conditional approvals that prioritize timely access without sacrificing reliability. In parallel, strategic partnerships among diagnostics manufacturers, academic groups, and public health agencies are accelerating validation studies, enabling faster adoption of innovative assays. Taken together, these changes are driving a more agile, connected, and clinically integrated approach to dengue testing that prioritizes speed, accuracy, and operational fit.

Assessing the 2025 United States tariff-induced supply chain adjustments, procurement responses, and strategic implications for diagnostic sourcing and operations

The introduction of new tariffs in the United States in 2025 has introduced a layer of complexity for organizations procuring dengue diagnostic components and finished assays. Tariff measures applied to imported instruments, reagents, and certain assay components have increased the direct cost of sourcing specific items from affected jurisdictions, prompting procurement teams to re-assess sourcing strategies and total landed cost. Suppliers and health systems have responded by reevaluating supplier portfolios, seeking regional manufacturing alternatives, and restructuring distribution agreements to mitigate immediate cost exposure.

Beyond procurement cost pressures, the tariff environment has influenced supply chain design and inventory management. Organizations with limited domestic supply options have increased safety stock levels and extended planning horizons to buffer against import cost volatility and potential lead-time increases. Suppliers have accelerated efforts to localize production of critical inputs, including readers and thermal cyclers, as well as key consumables and reagents, though such initiatives require capital investment and time to realize. In the interim, some buyers have negotiated longer-term contracts to secure supply at predictable prices, while others have diversified their supplier base to distribute risk.

The tariff-driven reconfiguration has also affected competitive dynamics. Manufacturers with vertically integrated supply chains or local production footprints are gaining relative advantage, as they can offer more stable pricing and shorter lead times. Conversely, smaller suppliers reliant on cross-border sourcing face pressure to justify pricing and demonstrate continuity of supply. Public health programs and hospitals operating under constrained budgets are particularly exposed to these shifts, prompting re-prioritization of procurement toward assays and platforms that deliver the most clinical utility per dollar and that minimize exposure to tariff-affected inputs.

Deep segmentation-driven diagnostic insights describing how test types, technologies, end users, product formats, settings, and sample matrices determine deployment choices

Understanding segmentation dynamics is essential to selecting appropriate diagnostic strategies and aligning product portfolios with user needs. When viewing the landscape through the lens of test type, there are clear clinical and operational trade-offs among antibody, antigen, and molecular options. Antibody testing, split into IgG and IgM assays, serves useful roles in retrospective exposure assessment and seroprevalence work, while antigen testing-comprising NS1 enzyme-linked immunosorbent assays and rapid NS1 tests-supports early detection with the benefit of speed. Molecular testing, including conventional PCR and real-time PCR approaches, remains the standard for confirmation where high analytical sensitivity and genotype information may be required.

Technological segmentation further influences adoption. Enzyme-linked immunosorbent assays continue to underpin high-throughput laboratory operations, whereas lateral flow immunoassays, differentiated by colloidal gold or fluorescent readouts, enable true point-of-care deployment with varying degrees of quantitative capacity. Microarray platforms add multiplexing capabilities that are valuable in differential diagnosis scenarios and in research settings, and polymerase chain reaction technologies, from conventional to real-time formats, provide the backbone for sensitive and specific viral detection that informs clinical decision-making and surveillance.

End-user considerations also drive product selection and implementation strategies. Clinics and point-of-care environments favor rapid, user-friendly formats with minimal instrument dependence; diagnostic laboratories emphasize assay reproducibility and throughput; hospitals balance the need for both rapid triage and confirmatory testing streams; and research institutes require platforms that support methodological flexibility and in-depth analyses. Product type segmentation highlights complementary commercial approaches: instruments and readers, which include thermal cyclers and digital readers, underpin platform-dependent assays; software solutions enable connectivity, data analytics, and results management; and test kits deliver the consumables required for routine testing operations. Finally, setting and sample type choices shape logistics and validation strategies, with central laboratories providing controlled environments that support complex workflows and point-of-care settings necessitating robustness across plasma, serum, and whole blood matrices. An integrated view across these segmentation dimensions reveals where investment in instrumentation, biochemical chemistry, and operational enablement will yield the greatest clinical and commercial returns.

Regional diagnostic priorities and implementation realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape procurement and deployment strategies

Regional dynamics shape how diagnostics are prioritized, validated, and procured, with distinct operational realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and considerable private-sector participation favor a mixed model of centralized molecular testing supplemented by point-of-care antigen testing in outpatient and emergency settings. Regulatory frameworks in certain countries provide clear pathways for emergency use and post-market surveillance, enabling manufacturers to scale distribution while demonstrating real-world performance.

Europe, the Middle East & Africa present a mosaic of adoption patterns influenced by national regulatory regimes and heterogeneous healthcare infrastructures. High-resource markets in Europe emphasize harmonized validation standards and integration with electronic health records, while markets across the Middle East and Africa often grapple with logistical constraints that drive demand for robust, low-maintenance assays and point-of-care platforms that tolerate variable cold-chain conditions. Collaborative procurement mechanisms and donor-supported initiatives play a meaningful role in driving access in lower-resource settings.

Asia-Pacific exhibits strong demand for both high-throughput laboratory solutions in metropolitan centers and rapid diagnostic options for decentralized clinics across endemic regions. Several countries in the region have developed local manufacturing capacity, which influences pricing and supply resiliency. Cross-border collaboration and regional surveillance networks have strengthened, fostering data sharing and harmonized response strategies. Taken together, these regional characteristics underline that diagnostic selection and deployment strategies must be tailored to local infrastructure, regulatory pathways, and epidemiological context to achieve effective case detection and public health impact.

How diagnostics companies are aligning product portfolios, manufacturing resilience, and digital capabilities to deliver integrated dengue testing solutions and secure supply chains

Leading firms and innovators in the dengue diagnostics ecosystem are responding to emergent needs through a combination of product development, strategic partnerships, and investments in manufacturing resilience. Companies with diversified portfolios that span antigen, antibody, and molecular offerings are positioned to meet multi-tiered clinical pathways, providing rapid screening at point-of-care and confirmatory testing in centralized laboratories. Strategic collaborations between assay developers and instrument manufacturers have accelerated the availability of integrated solutions that reduce validation burden for end users and shorten time-to-clinic deployment.

Commercial strategies increasingly emphasize connectivity features and software-enabled services that enhance the utility of diagnostic platforms. Companies that offer readers or thermal cyclers paired with secure data management systems enable laboratories and public health agencies to collect and analyze testing data more efficiently, improving case tracking and resource allocation. In addition, manufacturers that have invested in regional production or established distributed manufacturing partnerships are seeing tangible benefits in terms of supply continuity and responsiveness to tariff- or logistics-driven disruptions.

Innovation is also manifest in go-to-market approaches. Organizations that support end users through training, localized validation support, and bundled service agreements reduce implementation friction and build long-term adoption. Smaller specialized developers contribute to the ecosystem by delivering niche or high-performance assays that can be licensed or co-branded with larger platform providers. Collectively, these corporate behaviors underscore a shift toward integrated solutions that combine assay chemistry, hardware, and digital infrastructure to meet the practical demands of diverse healthcare environments.

Actionable strategic steps for diagnostics leaders to strengthen supply chains, accelerate point-of-care innovation, and integrate digital connectivity to drive adoption

Industry leaders should act decisively to align product development, supply chain strategy, and customer engagement with the evolving realities of dengue diagnostics. First, prioritize diversification of sourcing and consider regional manufacturing partnerships to reduce exposure to tariff-induced cost volatility and to shorten lead times for critical reagents and instrument components. Investing in flexible manufacturing contracts and dual-sourcing strategies will preserve continuity and create negotiating leverage with suppliers. Next, accelerate development and market readiness of point-of-care antigen and lateral flow formats with reader compatibility to meet demand for rapid triage and decentralized surveillance, while maintaining laboratory-grade molecular options for confirmatory testing and genotype analysis.

Leaders must also integrate digital enablement into product roadmaps. Embedding connectivity and standardized data export capabilities within instruments and readers will facilitate real-time case reporting, contribute to public health intelligence, and create value-added service opportunities. Concurrently, focus on end-user enablement by designing simplified workflows, providing comprehensive validation packages, and investing in training programs that reduce adoption friction. From a commercial perspective, offer flexible contracting models that account for procurement cycles in public health programs and hospitals, including outcome-oriented agreements and bundled solutions that combine instruments, consumables, and software services.

Finally, engage proactively with regulators and public health stakeholders to design validation studies that reflect real-world performance, including evaluations across plasma, serum, and whole blood, and in both central laboratory and point-of-care settings. Transparent post-market surveillance and robust real-world evidence generation will build trust and facilitate broader adoption. These combined actions will position companies to capture clinical relevance, maintain supply stability, and drive sustainable growth in an increasingly competitive and fragmented environment.

Rigorous mixed-methods research approach combining expert interviews, laboratory validation reviews, regulatory analyses, and supply chain mapping to produce operationally focused insights

This research synthesizes evidence from a structured, mixed-methods approach that combines qualitative expert interviews, laboratory validation reviews, regulatory guidance analyses, and a systematic review of peer-reviewed literature and technical white papers. Primary engagements included conversations with clinical laboratorians, infectious disease specialists, procurement leads, and diagnostic developers to capture frontline perspectives on assay performance, operational constraints, and deployment considerations. Laboratory validation reviews examined reported analytical sensitivity, specificity, and operational characteristics for representative assays across antibody, antigen, and molecular categories, with attention to sample matrix compatibility and instrument requirements.

Regulatory guidance and policy documents were analyzed to understand approval pathways, emergency use provisions, and post-market surveillance expectations that influence time-to-adoption. The methodology also incorporated supply chain mapping to identify sourcing dependencies for instruments, consumables, and reagents, and to assess potential exposure to tariff and logistics disruptions. Where possible, findings were triangulated across data streams to increase confidence in conclusions and to highlight areas where evidence is limited or variable.

Limitations inherent to the methodology include variability in the quality and availability of performance data across assay types and the rapidly evolving nature of regulatory decisions and supply chain conditions. To mitigate these limitations, the research prioritized primary stakeholder input and validated laboratory findings against multiple independent sources. The resulting analysis aims to provide an operationally useful synthesis rather than definitive technical validation, supporting decision-makers in planning implementation and procurement strategies that account for both clinical and logistical considerations.

Concluding synthesis of diagnostic innovation, operational alignment, and supply chain resilience that defines effective dengue testing strategies and program priorities

The convergence of technological innovation, decentralization, and supply chain realignment has created both opportunities and operational challenges for dengue diagnostics. Rapid antigen and improved lateral flow formats are expanding the capacity for timely case detection at the point of care, while advances in PCR instrumentation and laboratory automation sustain the need for centralized confirmatory testing and genotypic surveillance. At the same time, external forces such as trade policy shifts have made supply chain resilience and sourcing strategy primary determinants of procurement risk and program continuity.

For practitioners and decision-makers, the imperative is clear: align diagnostic selection with clinical pathways and operational realities. This requires a nuanced assessment of test type and technology trade-offs, deliberate sourcing strategies to mitigate external cost pressures, and investment in digital and training infrastructure that reduces implementation friction. Organizations that adopt an integrated approach-combining robust point-of-care screening, laboratory confirmation where needed, and data connectivity-will be best positioned to maintain diagnostic continuity and to support effective clinical and public health responses.

Looking ahead, continued collaboration among diagnostic developers, health systems, and regulatory authorities will be essential to translate innovation into accessible, reliable testing programs. Stakeholders who prioritize supply chain diversification, real-world performance validation, and user-centered product design will accelerate adoption and improve outcomes for patients and communities affected by dengue.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of smartphone-enabled rapid molecular assays for dengue serotype differentiation in field settings
  • 5.2. Development of multiplex point-of-care diagnostics detecting dengue, Zika, and chikungunya viruses simultaneously
  • 5.3. Integration of CRISPR-Cas based fluorescence readout tests for rapid dengue viral RNA detection at point of care
  • 5.4. Emergence of high-sensitivity immunoassays utilizing nanoparticle-enhanced detection for early dengue diagnosis in low-resource settings
  • 5.5. Regulatory approval trends accelerating commercialization of at-home dengue antigen test kits with digital reporting capabilities
  • 5.6. Implementation of AI-driven algorithms analyzing patient symptoms and test results to predict dengue outbreak hotspots in real time
  • 5.7. Partnership models between biotech firms and public health agencies to scale dengue surveillance via mobile testing units in endemic regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dengue Testing Market, by Test Type

  • 8.1. Antibody Test
    • 8.1.1. Igg Antibody Test
    • 8.1.2. Igm Antibody Test
  • 8.2. Antigen Test
    • 8.2.1. Ns1 Enzyme Linked Immunosorbent Assay
    • 8.2.2. Ns1 Rapid Test
  • 8.3. Molecular Test
    • 8.3.1. Conventional Polymerase Chain Reaction
    • 8.3.2. Real Time Polymerase Chain Reaction

9. Dengue Testing Market, by Technology

  • 9.1. Enzyme Linked Immunosorbent Assay
  • 9.2. Lateral Flow Immunoassay
    • 9.2.1. Colloidal Gold Assay
    • 9.2.2. Fluorescent Immunoassay
  • 9.3. Microarray Technology
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Conventional Polymerase Chain Reaction
    • 9.4.2. Real Time Polymerase Chain Reaction

10. Dengue Testing Market, by End User

  • 10.1. Clinics
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Dengue Testing Market, by Product Type

  • 11.1. Instruments
    • 11.1.1. Readers
    • 11.1.2. Thermal Cyclers
  • 11.2. Software Solutions
  • 11.3. Test Kits

12. Dengue Testing Market, by Setting

  • 12.1. Central Laboratory
  • 12.2. Point Of Care

13. Dengue Testing Market, by Sample Type

  • 13.1. Plasma
  • 13.2. Serum
  • 13.3. Whole Blood

14. Dengue Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Dengue Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Dengue Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. F. Hoffmann-La Roche Ltd
    • 17.3.3. Thermo Fisher Scientific Inc.
    • 17.3.4. Danaher Corporation
    • 17.3.5. bioM9rieux SA
    • 17.3.6. QIAGEN N.V.
    • 17.3.7. Bio-Rad Laboratories, Inc.
    • 17.3.8. Siemens Healthineers AG
    • 17.3.9. Meridian Bioscience, Inc.
    • 17.3.10. Chembio Diagnostics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DENGUE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DENGUE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DENGUE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS DENGUE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE DENGUE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE DENGUE TESTING MARKET SIZE,